Practical Guide 2017

Our readership explodes: we have new projects, we need help! we are looking for translators and also voices for podcasts. Someone to animate via social networks would also be of great help! You like this blog, so, please help!

This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

Here is an exchange, a rather bad one ... One says:
This is called 'close the door behind you', much like former immigrants opposing ... immigration. And there is worse: each and every one has his own restrictions, taboos: according to them, descalation is not for you if CD4 are less than ... If your CD4/CD8 ratio is less than ... If your reservoir is... If your combo is not X or Y ... Etc. All this is rigorously FALSE!

Without an informed, well-argued deciphering, it sparks in all directions: this is all FAKE-NEWS

A Practical Guide to Avoid Misunderstanding

Update of the Practical Guide SAFE 4/7: ANRS-4D introduces a PREMIUM eligibility and the Morlat 2016-2017 report explicitly authorizes ICCARRE, without any practical information, without citing all the trials, which would have been useful and honest. There is a great advantage: by saying nothing, it saves us the usual bullshit! Pr Rouzioux-of-criteria ate her hat!

The Morlat report is the usual useful idiot, silly and useless, unusable and unpractical. The reader, patient or doctor, is referred to just 2 trials, without the least bibliographic reference to ICCARRE. Morons!

This suits me a little, the patient searches on the internet and invariably gets to the Practical Guide, a very downloaded document, and for medical advise, on our list of doctors. She's out of trouble! Good!

The Practical Guide is enriched accordingly. It is available in French, English, Portuguese, Spanish (soon) and Arabic (indeed. It is not claimed to be perfect, nor to be a substitute to a doctor, expert-in-that-very-matter (Beware of incapable, ignorant, incompetent or liars and ... counterfeits)

The 2016 version differs from the 2015 version:

ANRS-4D revolutionizes the short cycle; The 2016 version therefore differs from the 2015 version:
- Eviplera® (Complera®) is tested: 100% successful
- Premium eligibility: Short Cycle is more appealing
- Direct to 4/7, under eligibility conditions: validated
- In patients, strictly eligible and strictly observant, the VL has never picked up: in this context, our rule of frequent VL can reasonably be reconsidered (even if I keep liking it, but I am incapable to prove it is indispensible

Looking at at the rare (very very rare ...) personal testimonies of failures, one inevitably finds failure to follow of one of the three rules: Efficiency, progressivity, frequent VL. And Shit happens ... Well, always easy repaired (eg back to 7/7) ...

Premium Eligibility

Progressivity: Well ... I prefer progressivity, because I went through the anguish of 6/7 (I was scared!). Perhaps useless, it did not cost me.

Frequent VLs: People have trouble with this; VLs detect a loss of efficiency as soon as possible. It is the other side of the efficiency coin. If one is sure of the efficacy, very sure, what about the need for frequent VLs (month-1, m-2, m-4, m-6 ...)? Okay... But true efficiency is proved with ... VL!

Efficiency: many presume drug's efficiency ... Yes, they have been given the latest very modern, very pricey, so well marketed that they neglected all warnings. This medicine, imperfect, is better sent to the sewer. ANRS-4D formalizes the Premium eligibility, which is already in ICCARRE (if you can decypher), not in the others, an additional proof that ICCARRE is not a simple sequel.

conditions	Simple Eligibility	Premium Eligibility
a priori efficiency validation	No	Yes (genotype required)
validation of usage efficacy	2 successives UD VL	3 times VL < 50 (make sure it is undetectable)
minimal duration of current ART	12 months	4 months
Advantages	no Genotype	4/7 direct frequent VL unnecessary?
disadvantages	6/7, 5/7; frequent VL	Genotype required or redone

ICCARRE method of to redo a genotype or regain sensitivity is stunning! It is a Septist's nightmare and,therefore a good reason to explore it! And we'll get back to it!

What about ANRS-170-Quatuor?

Announced for the end of 2016, then by act-up for July 2017, it will be good enough if it ever starts one day! We are being put off. Results for 2020! At best ... Well ... I hope noone is fooled by this little game.

It is merely the continuation of the ANRS-4D trial, which coordination had been entrusted to Mmes BENALYCHERIF and AMAT (phone: +33 (0)1 40 25 63 65, email: aida.benalycherif... followed the at sign then by ...gmail.com et karine.amat... followed the at sign then by ...hotmail.fr). You should be able to find more there.

Morlat already authorizes ICCARRE, then, what is the point with ANRS-170-Quatuor? What's the point?

This blog is not a medical advice: For this strategy, see Dr. de Truchis (see list). What about others? Well ... Why the copy when we have the original? Ignore the ignorant, and go to one of these docs, Practical Guide in hand. Move your ass! And report!

Today, is the first of Ramadan: our elders have understood the benefit of 'breaks', also of the Shabbat breaks. Since Copernicus, we have a much better understanding of rhythms! Good Ramadan to those who celebrate it, and Good Shabbat and Good fuck to all the others!

Our readership explodes: we have new projects, we need help! we are looking for translators and also voices for podcasts. Someone to animate via social networks would also be of great help! You like this blog, so, please help!

This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

First-line Tivicay Monotherapy

First-line Tivicay Monotherapy
This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

First-line with Mono-DTG

By Charles Edouard!

Here is a topical question:

For medical advice, see Pr Katlama or Dr. Lanzafame. What do the tests say? In monotherapy, in ING 111521, 90% of patients passed the <400 mark in just 10 days! Lanzafame initiates the Tivicay ® monotherapy, from the first prescription. As first-line, DTG + 3TC Bitherapy worked well. The proposals DTG + 3TC or Tivicay ® + Truvada ® are not coformulated: they allow monotherapy: just leave the other one in the closet. Dr. Lafeuillade recounts a personal experiment ...

Will the Wainberg hypothesis be validated by Lanzafame?

On a 'wild' (non-mutated) virus, the first mutation to appear is R263K. But it prevents the virus from regaining strength (loss of fitness), and, the reservoir should 'normally' decrease: it falls into a Darwinian black hole .... Adios asshole!

Conversely, if the virus has step-stone mutations or substitutions (I simplify), it can acquire resistance mutations; The benefit of R263K is lost, and that of mono-Tivicay® as well ...

If the Wainberg concept is correct, then, we should see at the clinic:
- a rate of success not too bad, not too good, on already mutated viruses (eg failure to RAL or EVG), and this is what we observe (Viking trial)
- a success rate, in maintenance monotherapy, which depends on the presence of the footsteps: this is what is observed in the BMM + P cohort: it is the Achille's heel.
- an excellent success rate, in first-line on wild type virus: this is what we observe (ING test 111521 + Lanzafame report)

If the Wainberg / Mesplede theory (the R263K pathway is beneficial) is accurate, the success of DTG monotherapy should not depend on any parameter other than wild-type (or not) nature.

Tivicay® Monotherapy with Naïve Patients: Yessss!

Hence the importance of the latest publication by Dr. M. Lanzafame, who further increased his group of patients using Tivicay® monotherapy as their first therapy (wild virus and a VL <100.000).

Lanzafame saves the medical honor ... and the world!

He has redone ING 111521: it is a prudent scientific approach, to confirm the results of a commercial trial... This is in line with the result of ING 111521, unexpected at first, then put under the rug or even occulted later.

He chooses his patients, with restrictive conditions on the virus, the 'wildest' possible. And none on CD4: one patient had CD4 = 1, another CD4 = 2!

Lanzafame unveils a new strategy. His patients (why not you?) will therefore benefit from an effective monotherapy, as first line, which opens the door to an alleviation like ICCARRE 4/7. His group will be able to move closer to remission ('cure').

He invites us to reconsider the results of BMM + P (Barcelona, ​​Montreal, Munich) + Paris, where, with selected patients, we have excellent results, contrary to the DOMONO protocol, where patients are not or poorly chosen, and where the result is mediocre.

Obviously, no one told you about this !! If the ignorants and traitors tell you that mono-Tivicay® does not exist, well, now you know that it does... The subject is relaunched from the ethical, clinical, public health angle: we will discuss this soon ...

This blog is not a medical advice: For this strategy, get in touch with Dr Katlama, Lafeuillade or Lanzafame (see list). What about others? Well... They are lagging behind, so you ignore the ignorant, and you go to one of these 3 doctors. Move your ass! And report here!

In this election weekend many will have to swallow a bitter snake...
Not me! This weekend is my first without meds: it is the first of my return to 1/14! And it is real cool!

Comments

Nanar May 21, 2017


Charles-Edouard! May 21, 2017



This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

beyond 1/7

This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

The other side of the 1/7 mirror

By Charles Edouard!

A tribute to Patrick Valas, the first ICCARRE blogger: the only known mention on better than 1/7!

Dixit Leibowitch:

They dreamed of it, Charles-Edouard did it!

The Eclipse lasts ... from 7 to 35 (*) j ... Thus ...

# intake  1 / X   VL   1 7   <20   2 9 3 9 4 9 5 9 6 9 7 9 8 11   <20   9 11 10 11 11 11   <20   12 11 13 11 14 12   <20   15 11 16 11   <20   17 14 18 13   <20   19 14 20 15   <20   21 14 22 14   <20   23 14 24 14 25 15   <20   26 16 27 17   <20   28 17 29 19   <20   30 22   <20   31 20 32 22   <20   33 27 20<VL<200

Obviously, protocolization implies that we limit ourselves to 1/7 ... Yes, but Leibowitch's recipe is a MOAB (mother of all bombs)! And it works wonders. When one is in the right alignment of stars, that one is not bound to the injunctions of the Master, that one writes regularly on 4/7, 1/7, well, one asks necessarily the question: what about beyond 1/7: Exactly as Leibowitch evoked it; 2 or 1/10, then on 14, etc ... We will go to look for the limits of our own system, and then adjust. Its miracle is the Eclipse He or She, infedded or not even concerned, does not rule: the Virus is the sole decider, it rules as an absolute master, and its miracle is the Eclipse! As long as the Virus does not go up, it does not go up: it's just as simple as that. There is no known reliable predictor, not even proviral DNA as demonstrated, conversely, CHUN in Toronto: moreover we don't give a damn: you measure the Eclipse, then YOU decide. The table opposite is my ICCARRE schedule beyond 1/7, with 1/X going on, without the slightest blip, up to 1/22, easy... Beyond, at 1/27, it trips... Fine ... We make a note... The 190 eligible and observing patients have ZERO intrinsic failures at 4/7, and now we quibble to launch the QUATUOR trial! With this experiment, I learned a lot... In retrospect, I should have done an analytical interruption, with a weekly step: Ananworanich tells us that the average is at approx. 21 j. (*): I'm just an average patient! Nothing special! And this was before Dolutegravir (Tivicay ®) arrival which opens new horizons.

Well ... So when I 'm being told that I'm in tow behind Leibowitch, it makes me smile ... This is no beauty contest. It is a strategy based on observable facts: I have an eclipse of a little less than a month, so I set the cursor at 15 days.

With the good old patent, I made almost an entire year at 1/14 and better, just count the days on the table ;-)

I passed the 6 months beacon with the wonderful Tivicay® 50mg + 3TC 300mg: 5 months on Sat. + Sun and 1 month on Sundays, double dose: always <20!

We are May 1st and I try again at 1/15, ie, Remission-24 (I will explain ...) with a whole new method.

What to do with the advice of good old Pr. Péronne, who orders to wait for the end of that trial, then for the next one, and then whatever else? I plug them where they deserve to be!

Happy MayDay, good fuck, and not too many meds! OK?


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

In Memoriam: Mark Wainberg
This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

In Memoriam: Mark Wainberg

By Charles Edouard!

Breaking News, Apr. 29: contrary to desappointing DOMONO, we will publish news from Tivicay & reg; Monotherapy, on 20 patients, another Charles-Edouard! exclusive!...

The blog is very much read, including by specialists ...

Leibowitch gave us many gifts: Stalingrad, ICCARRE, of course, the previous post, which was a great success, and to be back to combat, with force.

In my next posts, I will expose my new project: a trick that goes a little further ...

It was conceived in Leibowitch's universe with an incontestable contribution by Mark Wainberg (and his usual co-author: Thomas Mesplède): this project is inspired by ICCARRE (the Eclipse, for short), and work by Wainberg / Mesplede.

The Wainberg proposition, which I shall explain soon, resonates (reasons?), detonates like Leibo. Wainberg's (wikipedia) scientific production, aloof for a while, had been revived ...

Bad luck ... Swimming at sea, despite a red flag: fatal drowning: see cf CBC News and Le Monde

His YouTube interview inspires our Tivicay ® Mono page (original in French)and DTG exploration.

Politically active, president of various institutions, Dr. Wainberg also opposed AIDS denialism, which has caused about 330,000 deaths in South Africa alone ... He campaigned for better access to testing for 90-90-90 (see here), which we will discuss soon.

My reader, here, enjoys, as she might suspect, innovative ideas: things keep moving... There will be news from Leibowitch, again, news from Lanzafame, next week or so ... news from Biosantech ... 2017 will be a Wainberg/Mesplede vintage.

The PreP with, as an alternative to Truvada®, a mono or bi of Tivicay®, is Wainberg's.

Exploring and exploiting the causes of the Achilles' Heel is from Wainberg/Mesplède.

It is credited with use of Lamivudine (ViiV's Epivir®) as ARV, (see Bernard Belleau); He had published extensively on Dolutegravir (ViiV's Tivicay®). And what do I take? Lamivudine + Dolutegravir (only once a week, on top of that...)

Wainberg made possible Biosantech's Warholian 15 min. of glory: we will get back to this.

I had explained him the trick in DTG power experimental limit, here (original is here): we laughed (you too ...) and since then, our exchanges were regular, always very interesting, albeit not frequent.

I am sad, of course, but I had the chance to talk with him, to fancy about what will soon be possible, before a moment of inadvertence took him away from us. How lucky I have been!

Wainberg and beyond: he was full of ideas, projects, enthusiasm. He visualized eradication and remission. He was pleased with Nicolas Chomont's return to Montreal. Thomas Mesplède will continue the legacy, we hope!

In-memoriam Homage, of course! But let's do better: let's read his work and move forward to eradication and remission, which is our hope, which is the goal, and I think we're going to be right. We will win!

With all our condolences to his family, loved ones, coworkers, friends, ...

Note Dated May 11: a nice article by one of his former students, Eric J. Arts.

Breaking News, Apr. 29: contrary to desappointing DOMONO, we will publish news from Tivicay & reg; Monotherapy, on 20 patients, another Charles-Edouard! exclusive!...


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

ethics and elegance

ETHICS AND CHIC OF ICCARRE

By Dr. J. Leibowitch, Emeritus of the University

This was originally published here, in French. We provide this translate for your convenience, practical aspects may differ where you live.

15 years too late, the ANRS capitulates, French guidelines capitulates: abused patients will claim for justice: the ethical fault will be under the spotlights ... REJOICE !, Jacques Leibowitch, front runner explorer of viral strains, viral load, tritherapies, 1/7, high profile possible Nobel candidate, offers you this post!

ETHICS AND CHIC OF THE ICCARRE PROGRAM

By Dr. J. Leibowitch, Emeritus of the University

In denial of the oracles announcing a leaping retroviral devil within 24-48 hours after ARVs are stopped, ICCARRE[4]’s anti-HIV treatments in short cycles have established feasibility / acceptability / effectiveness, without unfitting virological failures.

For fifteen years since the above “universally agreed sentence", facts have affirmed their tenacious obstinacy : HIV, after having been made undetectable under a semester of nonstop synergistic ARVs, repeatedly demonstrated that it WOULD NOT rebound before one to several weeks following a temporary interruption of ARVs.

The responsible physician must be wary of edicting “regulatory over-medication”, be it to shield timorous colleagues, or safeguard co- expert managers, or pacify restless antiviral manufacturers ....

Indeed, the benefits of ICCARRE’s short medicinal cycles lie primarily with ethics and deontology. The liable prescriber is expected to adjust prescriptions to their Necessary and Sufficient Best, to achieve and sustain designated therapeutic objectives (a viral load continuously <50 copies in the long run), when factual reality invites to it = commands it !

Initiated in 2000-2004 by Dybul et al, intermittent maintenance treatment in short, 7 days On / 7 days Off cycles founded its plumb on the 7 to 21 days which regularly separate the interruption of effective ARVs and HIV rebound, in the 2nd phase of ARV therapy which regularly trails after a hearty attack treatment.

In addition, pilot studies on intermittent therapy in short cycles have shown the mitigation of iatrogenic effects, while responding to patient’s demands that prescribers take into consideration the psychological/physiological constraints of unabated therapy.

Beyond ethics and deontology, alleviating constraints and costs under ICCARRE may be the compelling cherry on a compulsory cake : primum non nocere, there is no deontological commendation for over-medication !

Interrupting ARV treatment without instant HIV rebound is made possible by the physiology of the HIV reproduction process in vivo : it pendularly oscillates from a slow linear sub-50 copies growth to an explosive exponential development, returning to soft slowiness under unrelenting ARV co-operation, an OFF to ON dynamic contingent to the internal biophysiological or pharmacological environment.

And whether OFF ARVs, or within the time interval spanning from silent inoculation to blatant primary infection, it takes from 7 to 21 days and more for HIV to deploy its exponential multiplication phase, starting from its submerged slowish growth phase.

That periodicity gives an almost mathematical readability to the observed post-antiviral deference of HIV rebounds, alias post-antiviral delay, anergy, eclipse, sideration … Matters that breach the conventional wisdom on the so-called necessity to never abate on anti retroiviral therapy.

Re-read, think like Hippocrates, not like hypocrites, and ask your questions in the comments section below! Also think about getting in touch with ICCARRE users group!

Breaking News: Pr F. Dabis appointed as ANRS director

[1] Anti Retroviral Therapy; [2] Anti Retro Virals; [3] Persons Living With HIV; [4] Intermittent, in Canny short Cycles, Anti Retrovirals may Retain Efficacy

Comments

Anonymous April 23, 2017 at 12:06 PM




This was originally published here, in French. We provide this translate for your convenience, practical aspects may differ where you live.

I'm back to 1/7

I'm back to 1/7


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

This postcard made my day!

I assume you feel a little better than with Stribild®, 7/7. No? Do you believe me now?

I'm back to 1/7, with Dual Therapy, this time!

I have, in view, the last beacon that validates 2/7 (50 mg DTG + 300 mg 3TC), Saturday and Sunday. This is the last beacon, at 6 months. After, the project is to move to 1/7: 100 mg DTG + 600 mg 3TC, on Saturday; With a blood test on Saturday, if not on Friday, it suits me just as well...

For the average Joe-in-the-street, the 2/7 (DTG + 3TC), should be doable... We will see in a few weeks ... Especially since I already validated 4 months.

But, well ... I have lived for a long time with Leibowitch's 1/7 (1 NNTI + 3 INTI), and, there is just one thing to say: this 1/7 works Great! So, I'm going to be a little ahead of the call, and I've already started 1/7 (100 mg DTG (crunched or broken, with a meal) + 600 mg 3TC) since last Saturday.

I plan to try, once again, at 1/30! I say: once again at 1/30 ...

If you have 100% success, you have overdosed!

In alleviation, a basic principle: if at x / 7 an clinician-experimentalist has a perfect result, at least equal to that of the Septists (7/7), it is because she lacked ambition.

Having excellent results (cf Hocqueloux or Reynes) makes it possible to publish a good paper; It is also necessary to remain on a plateau, to ensure that it is sustainable.

But why the hell stop there ???

Even French guidelines authorizes the 4/7, whereas Tivicay® Monotherapy, will, at most, be open only to those who have avoided the Achilles Heel: the picture is clear:

First ICCARRE, second the Bi / mono of Tivicay®

First choice: the short cycle (ICCARRE), ideally 1/7
Second choice (for the anxious, forgetfuls or mutated viruses): Bi Tivicay® + 3TC. With possible extension, with some reservations (in particular because of Achille's Heel, which is present in 50% of failures, in BMM + P), to DTG as monotherapy (including, I know some pionners, in 4/7...)

But hey, I'm eligible for the Short Cycle, especially at 1/7, which I have experienced well enough.

Why the hell did I bother to leave Leibowitch's Short Cycle? The availability of DTG! Elementary, my dear Watson!

It was well worth trying! Among the disadvantages, a small depressive trend, strong in some, and that, we did not know say too much ...

As far as I am concerned, therefore, 7/7 with DTG, it will be a NO GO.

I used DTG 12.5 mg (1/4 of a pill, 7/7), for 6 months, it worked, thank you, but my first choice is the short cycle! And not the basic 4/7, please!

Exploring the formulas based on DTG will have allowed me to:
- better understand it
- explain, with full knowledge of the facts, to those many readers eager for this formula
- rethink, simplify, extend my Leibowitchian formula
- make new friends

Message to Leibowitch's Formula nostalgics: there is a Leibowitch before, an epiphany (Eureka!) Leibowitch and also a post-Leibowitchian future, which will see his hopes come true.

In the coming months, I will address two barely touched subjects:

ICCARRE, is a possibility for remission ICCARRE is a possibility for eradication

I also want to discuss the BIOSANTECH vaccine: the results are poorly presented, but with an ICCARRIAN perspective, it is potentially a killer.

I will also help defuse an unnecessary controversy, which runs among ICCARRIANS: ICCARRE is, certainly, a fight against overmedication (which Prep is not, obviously). It is above all one of the tools for eradication (PreP too, if it is affordable): Me, I am in FAVOR of PreP: see my Practical Guide PreP!

That is what is coming up, I will explain my argument later.

I measured my Eclipse: almost 1 month (but not 1 month ...), I kind of feel how to handle this.

With an Eclipse measured almost 1 month, I am an average patient: the average in recent studies shows it being 14-21 days, on average, knowing that it is in a Septist context, ie the most idiotic there is.

Post-Copernican science opens up to the world with a prediction, realized by the Eclipse. Yes the earth is round and No, the Australians do not fall out!

Eclipse! Eclipse! Good Lord!

Bring our sun back! Mr Farinelli (youtu.be/rqNrPV_3PpY)




This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

French guidelines authorize 4/7

By Charles-Edouard!

This was originally published here, in French. We provide this translate for your convenience, practical aspects may differ where you live.

In memoriam to Greg, a fighter who passed away in Jan. 2017, and had written:

Farewell, friend ... Overdose for a pathology impairs the treatment of others. Overdose of Tritherapies ... How many deaths?

Morlat capitulates! You didn't know ??

In France, the 'experts' report serves as guidelines, is written under the auspices of ANRS (and bears the name of its main author, Pr. Morlat: It has become 'A Confederacy of Dunces', a kind of biblical vademecum. Cite it and you are left alone, but if it is not in there, you are doomed...

This is the dung of the mind, but as it is worse elsewhere, we have to bear with it...

As early as 2016, it is known that the famous Morlat report will authorize ICCARRE 4/7; See my post here. This is presented at SFLS (Oct. 2016, p.17)

Well, since it's announced, we wait for the final text, so to share a laugh ...

Written in Nov. 2016, but online in Jan. 2017: no one dares talk about it ... You could look for it forever... It is well hidden in the bottom of a drawer: it is here! Lucky You! Now, you know about it.

How can traitor media be confounded?

The Morlat report aims at being a consensus ... This is not the case: cf the controversy by Pr. RAFFI ... It is the convergence of interests, of those who write it (we will come back to this!)

We can stand the lack of credibility, under the auspices of the ANRS, for a short while... At one point, they have to throw in the towel ...

The (bribed?) media-enemies of ICCARRE are defeated: their silence is deafening!

As usual, this is simple: you list your favorite media and you mark the date when the information is on their ticker. It speaks volumes!

Victory: Decrease in the number of days of treatment: Discontinuous

Full Victory! Then, admit the whole truth!

Victory that they would like to hide, for you will have noticed the trick: there is no mention of the FAUCY-DYBUL, FOTO, or ICCARRE trials: they would have to admit an enormous and reprehensible delay!

And Dr. Faucy and Dybul (trial NCT00339456 in 2010), Dr. Cal Cohen (FOTO in 2004) and Dr. J. Leibowitch (ICCARRE as early as 2010) ?? Do they suck??? Or are they the marker of your guilty denial?

Since you can consider 4/7 under conditions similar to those of the studies carried out, why not learn about all these studies?... No?

The simplest way is the Practical Guide. You will see immediately if you can consider be included in case by case. Rest assured! 90% of patients are eligible: you are most likely one of these cases ...

Otherwise, you will still have Tivicay® monotherapy, which I must tell you, at first sight of the DOMONO trial (PDF here), it is not encouraging, except if you take into account the selection algorithm. As a precautionary measure, Tivicay® + Lamivudine combination therapy is interesting, even if you have not been able to avoid the Achille's Heel Trojan Horse.

Good Weekend and good fuck!


This was originally published here, in French. We provide this translate for your convenience, practical aspects may differ where you live.

Trials vs Real Life

This was originally published here, in French. For your convenience, we provide this translation. Practical aspects may differ where you live.

Is real life different from trials?

by Charles-Edouard! (in bad mood...)

One of our readers testifies here, Feb. 24. 2017:

Thank you notes are my only reward! Thanks to you too ...

We will soon get to DOMONO, and its mixed results, having in mind the BMM cohort (Barcelona, ​​Montreal, Munich), whose results, after use of a selection algorithm are very good.

Why is true practice so different from 'science'?

Following the excellent presentation by J. Blanco at CROI 2017, the attack is cheerfully applauded. As the controversy can not be substatiated (monotherapy works for selected patients), lobbying focuses on the form. This is waged by Dr Joel Gallant, adored by web readers (althought this is disputable as Joel Gallant serves as a paid consultant/scientific advisor to Bristol–Myers Squibb, Gilead Sciences, Merck & Co., Theratechnologies and ViiV Healthcare/Glaxo-SmithKline) .

The charge is against DOLUMONO. Read the original article by Dr. Celia Oldenbüttel (photo opposite, abstract here): read, re-read, it required a motivated consultant to find a fly in the ointment ... Gallant lends his name and bankable e-reputation. (I had been fooled myself, but no more!). Grrr !! Hang on, here is the "argument" (cf article):
In a nutshell, Dr. Oldenbuttel would have evaded her prior authorization obligations, offered individualized care, but to many patients, so to get a mini trial, surreptitiousl, and get authorizations afterwards.

Bad faith, insinuations: beware of fakes!

The blame is extended to the other groups. Dr. Gallant even includes a factual error:
This is wrong !: the article by Dr. C. Gubavu [cf Hocqueloux, Orléans] states:
Dr. Gallant makes use of a (questionnable) US practice to create a misconduct by people merely enforcing their national regulations. Dr. Oldenbuttel measures GGT, CD4, CD8, lipids at the switch, that US doctors would supossedly not do: he sees the mark of a human experiment! My doctor does this tests, and with frequent follow-up. Who will blame Oldenbuettel? On the other hand, what do you think of those who do not ask for a complete panel and repeated blood draws, during a switch.

Dr. J. Blanco (opposite) explains why he makes this proposal to a patient, in front of him, with multiple failures. In a similar situation, what does Dr. Gallant do? Hmmm ??? Yet another switch with TRItherapy, then another TRItherapy, yet another TRItherapy, until the exhausted patient becomes 'lost to follow-up' (i.e. a cessation of treatment)?

Patients who have been (poorly?) treated badly with orthodox and abusive treatment take a leave with resulting health and epidemic damage. Guilt of US doctors, their standardized and ill-tolerated offering! They can escape legally (even ethically) but not morally. At least, Europeans have a suppression rate of 90%, where the US hardly gets to 50%! This kind of (sponsored?) lecturing is hard to swallow!

abusive nit-picking, "the argument" is spinned to commercial argumentation

The Germans overdo it: their technicality is unchallenged. The invisible, capitalist, hand exposes its voracious capture pattern: delay innovative trials, entrust them to the sacrosanct market players, and boo those who still practice their medical art with patients at heart.

J. Leibowitch, who contributed to the discovery of the virus, treatment, and alleviation much more than poor Dr. Gallant, was having dogs set on him, to the delight of the Great Capital.

Except that ... Except that ... The ANRS-4D trial , which was aimed at buying time and invalidating ICCARRE came back right on: ZERO intrinsic failure. Dr. Gallant knows how to find a fly on Dr. Oldenbuttel's ointment, but (how surprising!)> never mentions ICCARRE ...

The trial confirmed Leibowitch, who, for ICCARRE, had all necessary clearings. There is an exact match (ZERO intrinsic failure!) between the innovative team, and the formal ANRS test.

In Tivicay® mono it is the opposite: the BMM cohort, after proper screening (no Achille's heel, no poor compliance, nor initial viremia) gives good results. DOMONO, a randomized, inclusive trial, is a mixed success. A bit like IP monotherapy, authorized in France (on a case by case basis), and catastrophic in the MOBIDIP trial ...

Why does DOMONO leads to an interpretation opposite to that of BMM?

First, patients cheat ... They cheated in ANRS-4D, they cheated here too. The trial is in Amsterdam ... Where a high cheat rate and a 'I give the investigator the answer that pleases ...' effect has been reported. This is amplified by the linguistic problem identified here.
Dr. Vries-Sluijs comments (source):

Now, DOMONO is a cheater's realm and investigators credulity paradise !

Please explain how vL can go up with a perfect observance (sic) and without mutations of resistance (sic), yes! Please explain! On the other hand, patients who do not take their medicine and swallow 5 pills, the day before the blood test, that, I can understand!

In real life: ICCARRE

Many patients succeed in the Tivicay® mono: they are happy!

The price to pay for a safer Tivicay® monotherapy is not too hight:
- try, using a selective algorithm, the risk being low, and the harm null, and / or
- strengthen with Lamivudine (or Rilpivirine, should you prefer)

Many do not understand the Eclipse ... It's a pity! What can we do?

Eclipse is the necessary counterpart to chronicity. Your DNA is modified and now includes the recipe for apple pie [i.e. Of the virus ...]: it is not because your DNA has the recipe of the apple pie, that it begins to make apple pies like crazy!

The best solution: ICCARRE, and, the best ICCARRE is 1/7!

There, you have the choice between Leibowitch's patented formula or try to integrate Dolutegravir in your strategy (that is to say in 7/7, 4/7 or 1/7)

As far as I am concerned, both strategies worked very well. Then the little piss, the sold, the corrupt who sell their soup under cover of ethical concern, it disgusts me.

ICCARRE is good and above all ICCARRE is a tool for eradication ...

Note April 16: more fun? Try: How to make a clinical trial say whatever you want
And also more to come about Dr Joel. Gallant's own ethical issues : stay tuned

Good Weekend and good Fuck


This was originally published here, in French. For your convenience, we provide this translation. Practical aspects may differ where you live.